#3885
Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model
Introduction:
Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.
Conference:
Presenting Author:
Authors:
John Robbert D,
Guyot M,
Killian T,
Verslype C,
Lambrechts D,
Keywords:
Pancreatic neuroendocrine tumor,
Antiangiogenic immunotherapy,
single cell transcriptomics,
Immunosuppression,
#2297
Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?
Introduction:
Merkel Cell Carcinoma (MCC) is a rare Neuroendocrine skin tumour. MCC behavior is more aggressive than the more common Melanoma, with treatments often restricted to surgery or radiotherapy, although immunotherapy holds promise overseas. In 2008, a USA study identified an oncogenic polyomavirus (MCPyV) present in eight of ten tested MCC tumours. Studies from across Europe and the USA confirmed MCPyV presence in ~80% of all MCCs. However, a cohort from Australia found a rate of just 24%, suggesting an alternative mechanism; ultra violet (UV) exposure was suspected and later confirmed using genomic mutational signature analysis. Are these are two separate diseases, requiring different clinical management strategies for best patient outcomes?
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Robb T
Authors:
Robb T,
Woodhouse B,
Parker K,
Miller R,
Hayward G,
Keywords:
merkel,
ddPCR,
diagnostics,
genomics,
#2272
Enhancing Diagnostic Precision Through Combined Genomic and Histopathological Analysis of Pancreatic Neuroendocrine Tumors
Introduction:
Diagnostic differentiation of uncommon pancreatic malignancies can be challenging, but is essential for accurate clinical management; genomic analysis may provide a tool for making this critical distinction.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Lawrence B
Authors:
Robb T,
Yeong M,
Kramer N,
Blenkiron C,
Parker K,
Keywords:
precision medicine,
diagnostics,
histology,
pathology,
histo-pathology,
genomics,
